Reported adverse reactions include nausea, difficulty breathing, and, in rare cases, serious conditions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and renal dysfunction
To deliver those benefits to patients, however, companies will still need bigger investments from professional biopharma investors, venture capital funds, and from government agencies, and in an expedited manner, Bansal says
A starting tirzepatide dose of 2.5 milligrams roughly corresponds to the starting semaglutide dose of 0.25 milligrams in terms of tolerability and initial effect
10.1016/S0074-7742(09)87016-5 164 OliveiraA
Can you split Cagrilintide doses throughout the week
It doesn't mean BPC-157 is proven unsafe, but you shouldn't assume it's safe either